12 results about "Methemoglobin" patented technology

A method of treating a human subject which is effected by intermittent inhalation of gaseous nitric oxide at a concentration of at least 160 ppm is disclosed. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract. The disclosed method can be effected while monitoring one or more of on-site and off-site parameters such as vital signs, methemoglobin levels, pulmonary function parameters, blood chemistry and hematological parameters, blood coagulation parameters, inflammatory marker levels, liver and kidney function parameters and vascular endothelial activation parameters, such that no substantial deviation from a baseline in seen in one or more of the monitored parameters.

The purpose of the present invention is to provide a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, that does not cause side effects, and that has excellent quick-acting properties and a high antidote effect. Specifically, the present invention is a medicine that is for use in instances of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning, and that contains, as an active ingredient, at least one selected from the group consisting of hemeproteins capable of binding to a cyanide ion (CN-), a hydrogen sulfide ion (HS-), and an azide ion (N3 -), hemeprotein-containing substances capable of binding to CN-, HS-, and N3 -, and heme derivatives capable of binding to CN-, HS-, and N3. More specifically, the present invention is a medicine or pharmaceutical composition for treatment or prophylaxis of cyanide poisoning, hydrogen sulfide poisoning, and azide poisoning.

The present invention relates to a hemoglobin protein composition comprising biologically active hemoglobin and less than 2% methemoglobin (metHb) wherein the metHb is maintained below 2% after reoxygenation of hemoglobin. Furthermore, hemoglobin protein composition comprising biologically active hemoglobin and less than 25% of charge variants of total oxygenated hemoglobin. Moreover, the present invention also provides an effective concentration of antioxidant more than 5 mM used during heat treatment. The present invention provides pharmaceutically stable composition of hemoglobin. Furthermore, the present invention also provides a process for reducing and / or controlling the formation of metHb, charge variants and inactivation of viral and / or prion during manufacturing of oxygenated hemoglobin. In addition, the invention provides therapeutic use of oxygenated hemoglobin.

The present invention makes it easy to detect blood in milk regardless of whether the milk has been homogenized.　A method according to the present invention includes: a methemoglobin formation step S1 for changing hemoglobin contained in blood in a target sample derived from milk, which is a food product, into methemoglobin; a target exposure step for exposing the target sample to light; a target transmitted light detection step for detecting transmitted light from the target sample through a diffuser that diffuses and transmits the light; and a quantitative evaluation step for quantitatively evaluating the blood in the target sample on the basis of the intensity of light of a predetermined wavelength included in the transmitted light detected in the target transmitted light detection step.

The present invention is an in vivo non-invasive method and apparatus for the measurement of the arterial blood oxygen saturation status of a patient, the method is a generalized improvement on conventional pulse oximetry to correct for its skin pigmentation bias and significant errors in oxygen saturation assessment in the presence of methemoglobin. The method requires an additional red light sensor with an infrared long pass filter to conventional pulse oximetry, and utilizes red and infrared light and sensors to non-invasively measure the peripheral pulse optical plethysmograph waveforms (PPG) at three light wavelengths, red, long pass red and infrared, positioned over a finger, or ear or other extremity, and from the pulse oximetric ratio of ratios transforms the PPG measurements by a processing device that determines the subject's arterial blood oxygen saturation directly, without the need for an empirical correction as is required in conventional pulse oximetry. The method determines the red transmitted light waveform and thus quantifies the wavelength shift from the incident red light due to the subject's skin pigmentation, and from in vivo hemoglobin extinction coefficients, determines the relative concentrations of oxygenated and deoxygenated hemoglobin and methemoglobin in the subject's arterial blood.

To facilitate detection of bloody milk regardless of whether homogenization processing is performed.SOLUTION: A methemoglobin conversion step (S1) is performed to convert hemoglobin contained in blood derived from milk as a food product into methemoglobin in a target sample. A target irradiation step is then performed to irradiate the target sample with light. A target transmitted-light detection step is performed to detect transmitted-light from the target sample through a diffuser that diffuses the light while allowing it to pass. A quantitative evaluation step is then performed to quantitatively evaluate blood in the target sample on the basis of the intensity of light of a predetermined wavelength contained in the transmitted-light detected in the target transmitted-light detection step.SELECTED DRAWING: Figure 5

The present invention relates to the use of a formation agent, such as nitric oxide or sodium nitrite to produce methemoglobin as an alternative MRI contrast agent. The formation agent can be infused using either a respiratory system or a delivery mechanism. One embodiment of this invention relates to systems and methods for producing an image of an internal region with a magnetic resonance scanning system. Blood is drawn from the patient. The blood is exposed to formation agent through a delivery system, to produce blood that has a higher saturation of methemoglobin. Where in vitro techniques are used the treated blood is injected back into the patient. The patient is scanned in the magnetic resonance scanner. These systems and methods can be used to produce images of regions which may not otherwise be possible with other contrasting agents. For example, an accurate vascular brain MRI may not be as informative if the patient is injected with an existing contrasting agent. In addition, an alternate embodiment of the invention relates to internally exposing the blood to the formation agent by placing the gas-permeable membrane along a particular blood pathway or intravenous sodium nitrite.

A sensor assembly that enables the detection of hemolysis using a diagnostic analyzer. The sensor assembly can be housed in a diagnostic cartridge that attaches to the analyzer and can be supplied with sample fluid. The sensor assembly includes a primary oxygen sensor configured to provide a first measurement and a modified oxygen sensor that incorporates an oxidant configured to oxidize the iron in hemoglobin to methemoglobin and is configured to provide a second measurement. A hemolysis detection module of the diagnostic analyzer provides a hemolysis level in the sample based on the difference between the first and second measurements. Numerous other diagnostic analyzers, diagnostic cartridges, and detection methods are available.

A modular patient monitor provides a multipurpose, scalable solution for various patient monitoring applications. In an embodiment, a modular patient monitor utilizes multiple wavelength optical sensor and / or acoustic sensor technologies to provide blood constituent monitoring and acoustic respiration monitoring (ARM) at its core, including pulse oximetry parameters and additional blood parameter measurements such as carboxyhemoglobin (HbCO) and methemoglobin (HbMet). Expansion modules provide blood pressure BP, blood glucose, ECG, CO2, depth of sedation and cerebral oximetry to name a few.Aspects of the present disclosure also include a transport dock for providing enhanced portability and functionally to handheld monitors. In an embodiment, the transport dock provides one or more docking interfaces for placing monitoring components in communication with other monitoring components. In an embodiment, the transport dock attaches to the modular patient monitor.

The application discloses a CRISPR-Cas12a-based PGM signal detection myoglobin biosensor and a preparation method thereof. The application also discloses a qualitative and quantitative in-vitro myoglobin detection method. The application can achieve naked-eye observation detection effect and realize qualitative analysis of experimental results. In combination with a blood glucose meter, the application can realize low-detection-limit detection, and the detection limit can reach 1.32 ng / mL. The application simultaneously detects a test strip and the blood glucose meter, is simple and convenient to install and carry, and is low in cost. The sensor has good selectivity, and the detection results of other proteins can be obviously distinguished from the myoglobin.

A sensor assembly enabling hemolysis detection with a diagnostic analyzer. The sensor assembly can be included in a diagnostic cartridge that may be coupled to the diagnostic analyzer and a sample fluid can be delivered thereto. The sensor assembly includes a main oxygen sensor configured to provide a first measurement and a modified oxygen sensor including an oxidant configured to oxidize hemoglobin iron to methemoglobin and configured to provide a second measurement. A hemolysis detection module of the diagnostic analyzer provides a level of hemolysis in the sample based on a difference between the first measurement and the second measurement. Numerous other diagnostic analyzers, diagnostic cartridges, and detection methods are provided.

A sensor assembly enables hemolysis detection by a diagnostic analyzer. The sensor assembly can be included in a diagnostic cartridge that can be coupled to the diagnostic analyzer and can deliver a sample fluid to the sensor assembly. The sensor assembly includes a primary oxygen sensor configured to provide a first measurement and a modified oxygen sensor including an oxidant configured to oxidize hemoglobin iron to methemoglobin and configured to provide a second measurement. A hemolysis detection module of the diagnostic analyzer provides the level of hemolysis in the sample based on the difference between the first measurement and the second measurement. Numerous other diagnostic analyzers, diagnostic cartridges, and detection methods are provided.